Financial PerformanceNet loss was wider than expected due to higher operating expenses, driven by new product investment.
Product Launch And Market ReceptionEarly checks on iDose launch surprisingly mixed, with concerns existing around pricing, reimbursement, labeling, and procedure setting.
Regulatory ChallengesCurrent iDose label does not indicate reimplantation, with the company petitioning the FDA for a potential label update but with unclear timing.